Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open-Label, Multi-Center, Phase 3 Study to Evaluate the Efficacy and Safety of AP301 on Serum Phosphorus Control in Chronic Kidney Disease Patients Receiving Maintenance Dialysis With Hyperphosphatemia

NCT07030595 is registered in ClinicalTrials.gov with Alebund Pharmaceuticals as lead sponsor.

NCT NCT07030595
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07030595 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open-Label, Multi-Center, Phase 3 Study to Evaluate the Efficacy and Safety of AP301 on Serum Phosphorus Control in Chronic Kidney Disease Patients Receiving Maintenance Dialysis With Hyperphosphatemia
Lead sponsor
Alebund Pharmaceuticals
Phase
Phase 3
Overall status
Completed
Start date
June 12, 2023
Completion date
May 30, 2025
Enrollment
474 (actual)
Sites
50

Conditions

As the registry lists them; a condition with its own page is linked.

chronic kidney disease(ckd), chronic kidney disease, receiving dialysis, dialysis, esrd (end stage renal disease), hyperphosphatemia, hyperphosphatemia in chronic kidney disease